Literature DB >> 19766340

Incidence of isolated regional recurrence after definitive (chemo-) radiotherapy for head and neck squamous cell carcinoma.

Maarten Lambrecht1, Piet Dirix, Walter Van den Bogaert, Sandra Nuyts.   

Abstract

OBJECTIVE: To evaluate the incidence and localization of regional recurrences after definitive (chemo-) radiotherapy for head and neck squamous cell carcinoma (HNSCC).
METHODS: From May 1987 to March 2008, 368 patients with advanced HNSCC were irradiated to 66-80.5 Gray in 6-7 weeks, with (37%) or without (63%) concomitant chemotherapy (Cisplatinum 100mg/m(2)) every 3 weeks. No planned neck dissections were performed. Data on clinical outcome were retrospectively reviewed, location of the original nodal disease and the regional recurrence was indicated on imaging and correlated with radiation dose.
RESULTS: Mean follow-up was 34 months (range: 50 days-216 months). Three-year overall survival and disease-specific survival were 55% and 62%, respectively. Loco-regional, local and regional controls were 58%, 65%, and 80%, respectively. Forty-one patients (11.1%) relapsed in the neck, but only 11 patients (2.99%) developed a true isolated regional recurrence, 6 of whom could be successfully salvaged by surgery. Only 2 patients (0.54%) developed an isolated recurrence in the electively treated nodal levels.
CONCLUSION: Isolated nodal recurrences are uncommon and recurrences in the electively treated neck are extremely uncommon.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19766340     DOI: 10.1016/j.radonc.2009.08.038

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  8 in total

1.  Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience.

Authors:  D Van Gestel; D Van Den Weyngaert; D Schrijvers; J Weyler; J B Vermorken
Journal:  Br J Radiol       Date:  2011-04       Impact factor: 3.039

2.  Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.

Authors:  Fereshteh Ahmadinejad; Tasia Bos; Bin Hu; Erin Britt; Jennifer Koblinski; Andrew J Souers; Joel D Leverson; Anthony C Faber; David A Gewirtz; Hisashi Harada
Journal:  Mol Pharmacol       Date:  2021-12-14       Impact factor: 4.436

Review 3.  The role of neck dissection in squamous cell carcinoma of the head and neck.

Authors:  Marc Hamoir; Sandra Schmitz; Vincent Gregoire
Journal:  Curr Treat Options Oncol       Date:  2014-12

4.  Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC).

Authors:  S Skvortsov; J Dudás; P Eichberger; M Witsch-Baumgartner; J Loeffler-Ragg; C Pritz; V H Schartinger; H Maier; J Hall; P Debbage; H Riechelmann; P Lukas; I Skvortsova
Journal:  Br J Cancer       Date:  2014-05-01       Impact factor: 7.640

5.  Less may be more: nodal treatment in neck positive head neck cancer patients.

Authors:  Gabriela Studer; Gerhard F Huber; Edna Holz; Christoph Glanzmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-04-29       Impact factor: 2.503

Review 6.  Radiotherapy targeting cancer stem cells "awakens" them to induce tumour relapse and metastasis in oral cancer.

Authors:  Yangfan Liu; Miao Yang; Jingjing Luo; Hongmei Zhou
Journal:  Int J Oral Sci       Date:  2020-06-24       Impact factor: 6.344

7.  Epigenetic regulation of p62/SQSTM1 overcomes the radioresistance of head and neck cancer cells via autophagy-dependent senescence induction.

Authors:  Myungjin Lee; Hae Yun Nam; Hee-Bum Kang; Won Hyeok Lee; Geun-Hee Lee; Gi-Jun Sung; Myung Woul Han; Kyung-Ja Cho; Eun-Ju Chang; Kyung-Chul Choi; Seong Who Kim; Sang Yoon Kim
Journal:  Cell Death Dis       Date:  2021-03-05       Impact factor: 8.469

8.  Theranostic near-infrared-IIb emitting nanoprobes for promoting immunogenic radiotherapy and abscopal effects against cancer metastasis.

Authors:  Hao Li; Meng Wang; Biao Huang; Su-Wen Zhu; Jun-Jie Zhou; De-Run Chen; Ran Cui; Mingxi Zhang; Zhi-Jun Sun
Journal:  Nat Commun       Date:  2021-12-09       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.